Partnership3 Oct 2024, 03:43 pm
Emcure Pharmaceuticals to Manufacture and Supply Lenacapavir for Gilead in 120 Countries
AI Summary
Emcure Pharmaceuticals has signed a royalty-free voluntary licensing agreement with Gilead Sciences to manufacture and supply generic versions of lenacapavir. This agreement is part of a broader effort to increase global access to lenacapavir for HIV prevention and treatment, focusing on high-incidence, resource-limited countries. Emcure will ensure the availability of high-quality, low-cost versions of lenacapavir in 120 countries, primarily in low- and lower-middle-income regions. This strategic partnership underscores Emcure's commitment to innovative affordable global healthcare.
Key Highlights
- Emcure Pharmaceuticals partners with Gilead Sciences to manufacture and supply lenacapavir for HIV prevention and treatment
- Agreement focuses on increasing global access to lenacapavir in 120 countries, primarily in low- and lower-middle-income regions
- Emcure's expertise in manufacturing complex generic drugs ensures commitment to affordability and quality
- Lenacapavir is a long-acting option in multiple ongoing and planned clinical studies in Gilead's HIV prevention and treatment research program
- Emcure Pharmaceuticals is a leading Indian pharma company known for its commitment to innovation, quality, and patient-centricity